U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 52

1.
Levodopa‐Entacapone‐Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease: A Single‐Center Study of 30 Patients
Vili Viljaharju, Tuomas Mertsalmi, K. Amande M. Pauls, Maija Koivu, Johanna Eerola‐Rautio, Marianne Udd, Eero Pekkonen
Mov Disord Clin Pract. 2024 Feb; 11(2): 159–165. Published online 2023 Dec 10. doi: 10.1002/mdc3.13926
PMCID:
PMC10883392
AbstractArticlePDF–408K
2.
Comparison of two types of extension tubes for people with Parkinson’s disease in advanced treatment with levodopa–entacapone–carbidopa intestinal gel infusions: a prospective, crossover quality study
Trine Hørmann Thomsen, Louise Olsen, Mahsa Javidi, Nikolaj Folke La Cour Karottki, Bo Biering-Sørensen
BMJ Open Qual. 2024; 13(1): e002612. Published online 2024 Feb 15. doi: 10.1136/bmjoq-2023-002612
PMCID:
PMC10875519
AbstractArticlePDF–1002K
3.
Current and novel infusion therapies for patients with Parkinson's disease
Angelo Antonini, Valentina D’Onofrio, Andrea Guerra
J Neural Transm (Vienna) 2023; 130(11): 1349–1358. Published online 2023 Sep 6. doi: 10.1007/s00702-023-02693-8
PMCID:
PMC10645652
AbstractArticlePDF–728K
4.
Apprends-moi l'art des petits pas: Levodopa, Carbidopa Intestinal Gel plus Entacapone
Wolfgang H. Jost
J Neural Transm (Vienna) 2023; 130(11): 1379–1382. Published online 2023 Apr 28. doi: 10.1007/s00702-023-02625-6
PMCID:
PMC10645627
AbstractArticlePDF–484K
5.
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
Valentina Leta, Daniel J. van Wamelen, Federico Aureli, Vinod Metta, Dhaval Trivedi, Pietro Cortelli, Carmen Rodriguez-Blazquez, Alexandra Rizos, K. Ray Chaudhuri
J Neural Transm (Vienna) 2023; 130(7): 925–930. Published online 2023 Apr 10. doi: 10.1007/s00702-023-02603-y
PMCID:
PMC10293442
AbstractArticlePDF–698K
6.
FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms
Mahmoud S. Ahmed, Ayman B. Farag, Ian N. Boys, Ping Wang, Ivan Menendez-Montes, Ngoc Uyen Nhi Nguyen, Jennifer L. Eitson, Maikke B. Ohlson, Wenchun Fan, Matthew B. McDougal, Katrina Mar, Suwannee Thet, Francisco Ortiz, Soo Young Kim, Ashley Solmonson, Noelle S. Williams, Andrew Lemoff, Ralph J. DeBerardinis, John W. Schoggins, Hesham A. Sadek
Biomed Pharmacother. 2023 Jun; 162: 114614. Published online 2023 Mar 28. doi: 10.1016/j.biopha.2023.114614
PMCID:
PMC10043961
AbstractArticlePDF–12M
7.
Anti‐cancer effect of entacaponeon esophageal cancer cells via apoptosis induction and cell cycle modulation
Fahimeh Ramedani, Seyyed Mehdi Jafari, Marie Saghaeian Jazi, Zeinab Mohammadi, Jahanbakhsh Asadi
Cancer Rep (Hoboken) 2023 Mar; 6(3): e1759. Published online 2022 Dec 19. doi: 10.1002/cnr2.1759
PMCID:
PMC10026269
AbstractArticlePDF–1.7M
8.
Colite lymphocytaire associée à l’entacapone
David M. Rodrigues, Eugene Hsieh, Michael Bernstein, David N. Juurlink
CMAJ. 2023 Jan 23; 195(3): E132–E135. French. Publication en ligne 2023 janv. 23. DOI : 10.1503/cmaj.220680-f
PMCID:
PMC9876586
ArticlePDF–1.5M
9.
Lymphocytic colitis associated with entacapone
David M. Rodrigues, Eugene Hsieh, Michael Bernstein, David N. Juurlink
CMAJ. 2022 Oct 17; 194(40): E1377–E1380. Published online 2022 Oct 17. doi: 10.1503/cmaj.220680
Correction in:
CMAJ. 2022 Nov 15; 194(44): E1513.
PMCID:
PMC9616143
ArticlePDF–1.5M
10.
Clinical Pharmacology of Entacapone (Comtan) From the FDA Reviewer
Sam Habet
Int J Neuropsychopharmacol. 2022 Jul; 25(7): 567–575. Published online 2022 Mar 18. doi: 10.1093/ijnp/pyac021
PMCID:
PMC9352175
AbstractArticlePDF–554K
11.
Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
Thomas Müller, Eugen Schlegel, Stephanie Zingler, Hans Michael Thiede
Cells. 2022 May; 11(9): 1511. Published online 2022 Apr 30. doi: 10.3390/cells11091511
PMCID:
PMC9105632
AbstractArticlePDF–1.1M
12.
A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson’s Disease
Shih-Chen Fu, Chung-Han Lee, Yi-Chen Hsieh, Pei-Hua Wu, Sheng-Hsuan Lin, Hsiuying Wang
Front Cell Infect Microbiol. 2022; 12: 837019. Published online 2022 Apr 5. doi: 10.3389/fcimb.2022.837019
PMCID:
PMC9022099
AbstractArticlePDF–1.3M
13.
In vitro and in vivo characterization of Entacapone-loaded nanostructured lipid carriers developed by quality-by-design approach
Yogeeta Agrawal, Kiran Patil, Hitendra Mahajan, Mrugendra Potdar, Pratiksha Joshi, Kartik Nakhate, Charu Sharma, Sameer N. Goyal, Shreesh Ojha
Drug Deliv. 2022; 29(1): 1112–1121. Published online 2022 Apr 5. doi: 10.1080/10717544.2022.2058651
PMCID:
PMC8986208
AbstractArticlePDF–2.3M
14.
Key features of inhibitor binding to the human mitochondrial pyruvate carrier hetero-dimer
Sotiria Tavoulari, Tom J.J. Schirris, Vasiliki Mavridou, Chancievan Thangaratnarajah, Martin S. King, Daniel T.D. Jones, Shujing Ding, Ian M. Fearnley, Edmund R.S. Kunji
Mol Metab. 2022 Jun; 60: 101469. Published online 2022 Mar 10. doi: 10.1016/j.molmet.2022.101469
PMCID:
PMC8968063
AbstractArticlePDF–3.0M
15.
Catechol‐O‐methyltransferase inhibitors for levodopa‐induced complications in Parkinson's disease
Katherine Deane, Sybille Spieker, Carl E Clarke, Cochrane Movement Disorders Group
Cochrane Database Syst Rev. 2004 Oct; 2004(4): CD004554. Published online 2004 Oct 18. doi: 10.1002/14651858.CD004554.pub2
PMCID:
PMC8830033
AbstractArticlePDF–460K
16.
Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19
Maral Aminpour, Williams Ernesto Miranda Delgado, Soren Wacker, Sergey Noskov, Michael Houghton, D. Lorne J. Tyrrell, Jack A. Tuszynski
BMC Pharmacol Toxicol. 2021; 22: 61. Published online 2021 Oct 21. doi: 10.1186/s40360-021-00519-5
PMCID:
PMC8529228
AbstractArticlePDF–5.8M
17.
Entacapone Treatment Modulates Hippocampal Proteins Related to Synaptic Vehicle Trafficking
Dae Young Yoo, Hyo Young Jung, Woosuk Kim, Kyu Ri Hahn, Hyun Jung Kwon, Sung Min Nam, Jin Young Chung, Yeo Sung Yoon, Dae Won Kim, In Koo Hwang
Cells. 2020 Dec; 9(12): 2712. Published online 2020 Dec 18. doi: 10.3390/cells9122712
PMCID:
PMC7765944
AbstractArticlePDF–2.6M
18.
Population pharmacokinetics of levodopa gel infusion in Parkinson’s disease: effects of entacapone infusion and genetic polymorphism
M. Senek, D. Nyholm, E. I. Nielsen
Sci Rep. 2020; 10: 18057. Published online 2020 Oct 22. doi: 10.1038/s41598-020-75052-2
PMCID:
PMC7582154
AbstractArticlePDF–1.1M
19.
Evidence‐Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease
Andrew J. Lees
CNS Neurosci Ther. 2008 Spring; 14(1): 83–93. Published online 2008 Mar 14. doi: 10.1111/j.1527-3458.2007.00035.x
PMCID:
PMC6494077
AbstractArticlePDF–544K
20.
A Double‐Blind, Randomized, Placebo and Active‐Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease
Joaquim J. Ferreira, Olivier Rascol, Werner Poewe, Cristina Sampaio, José‐Francisco Rocha, Teresa Nunes, Luis Almeida, Patrício Soares‐da‐Silva, on behalf of the BIA‐3202‐202 Study Investigators
CNS Neurosci Ther. 2010 Dec; 16(6): 337–347. Published online 2010 Nov 9. doi: 10.1111/j.1755-5949.2010.00145.x
PMCID:
PMC6493781
AbstractArticlePDF–347K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed Central (PMC)
Support Center